MedTrace Logo

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT00949130 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2010-03-18

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of oral NXL103 vs. established treatment of acute bacterial infection in adults.

Conditions

  • Acute Bacterial Skin and Skin Structure Infections

Interventions

DRUG

NXL103

BID for 7-14 days

DRUG

Linezolid

BID for 7-14 days

Sponsors & Collaborators

  • Novexel Inc

    lead INDUSTRY

Principal Investigators

  • Michael Kuligowski, MD · Novexel Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States
  • Guatemala

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949130 on ClinicalTrials.gov